Afamelanotide

What is Afamelanotide?#

Afamelanotide (marketed as Scenesse) is a synthetic tridecapeptide (13 amino acid) analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It was developed by Clinuvel Pharmaceuticals and received EMA approval in 2014 and FDA approval in October 2019 for increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP).

The drug is also known by its research designation [Nle4, D-Phe7]-alpha-MSH (NDP-MSH), which describes the two key amino acid substitutions that distinguish it from native alpha-MSH and confer enhanced potency and stability.

Mechanism of Action#

Afamelanotide acts as a potent and selective agonist of the melanocortin 1 receptor (MC1R), which is expressed on melanocytes in the skin. MC1R activation triggers:

1. Eumelanin synthesis: Stimulates the production of eumelanin (brown-black melanin) rather than pheomelanin (red-yellow melanin), providing true photoprotection
2. Melanin distribution: Promotes melanin granule transfer from melanocytes to surrounding keratinocytes
3. Photoprotection: Eumelanin absorbs UV and visible light, providing a biological shield against phototoxic reactions
4. Anti-inflammatory effects: MC1R activation has anti-inflammatory and antioxidant properties independent of melanogenesis

In EPP, where excess protoporphyrin IX causes severe phototoxic reactions to visible light, the increased eumelanin acts as a photoprotective barrier, allowing patients to tolerate light exposure that would otherwise cause excruciating pain.

Clinical Significance#

EPP affects approximately 1 in 75,000-200,000 people. Patients experience severe, immediate phototoxic pain upon exposure to visible light, which cannot be prevented by conventional sunscreens (which primarily block UV). Prior to afamelanotide, no pharmacological treatment existed, and patients were forced to severely restrict outdoor activities.

Important Considerations#

Afamelanotide is administered only in certified healthcare settings through a subcutaneous implant procedure. It is not available as a self-administered injection. The drug causes skin darkening (tanning) as an expected pharmacological effect. Skin examinations are recommended before and during treatment to monitor for melanocytic changes.

Key Research Findings#

Afamelanotide for Erythropoietic Protoporphyria, published in New England Journal of Medicine (Langendonk JG et al., 2015; PMID: 26132941):

Phase 3 multicenter, randomized, double-blind, placebo-controlled trial evaluating afamelanotide 16 mg subcutaneous implant in adults with EPP across US and European sites.

• Afamelanotide significantly increased pain-free time in direct sunlight
• Acceptable side-effect profile with no serious drug-related adverse events
• Improved quality of life measures related to outdoor activities

Long-Term Observational Study of Afamelanotide in 115 Patients with Erythropoietic Protoporphyria, published in British Journal of Dermatology (Biolcati G et al., 2015; PMID: 25494545):

Long-term observational study following 115 EPP patients treated with afamelanotide in Italy over multiple years.

• Sustained benefit with repeated treatment cycles
• Significant increase in sun exposure tolerance
• Favorable long-term safety profile

Related Reading#

• Afamelanotide research studies and evidence
• Afamelanotide dosing protocols
• Afamelanotide side effects profile
• Melanotan-1 research guide
• Melanotan-2 research guide